Early Semaglutide Re-initiation Post-Sleeve Gastrectomy in Youth Aims to Improve Weight, Cardiometabolic Health

Severe obesity in youth is a growing public health concern, often leading to significant cardiometabolic comorbidities. While sleeve gastrectomy is an effective intervention, a substantial proportion of patients experience suboptimal weight loss or weight regain over time. Current standard care often lacks pharmacotherapy post-surgery, leaving a gap in sustained weight management strategies. GLP-1 receptor agonists like semaglutide have demonstrated significant efficacy in weight loss and cardiometabolic improvement, making them a promising candidate for adjuvant therapy to enhance and maintain the benefits of bariatric surgery, particularly in this vulnerable young population.

This is a Phase 3a, randomized, parallel-controlled trial designed to compare early re-initiation of semaglutide to standard care. The study will enroll 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care (no pharmacotherapy) for 24 months post-sleeve gastrectomy. Primary, secondary, and tertiary outcomes, including changes in obesity, cardiometabolic risk, and eating behaviors, will be assessed at 1-month pre-op, day of surgery, and 1, 3, 6, 9, 12, 18, and 24 months postoperatively.

This Phase 3a trial is currently in the design phase, and no empirical results are available yet. The study's core hypothesis is that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in key health metrics. Researchers specifically anticipate that semaglutide 2.4 mg weekly will significantly enhance outcomes in obesity, including sustained weight loss, compared to standard care. They also expect to observe superior improvements in cardiometabolic risk factors, such as HbA1c, blood pressure, and lipid profiles, as well as positive changes in eating behaviors. These benefits are hypothesized to manifest across multiple assessment points at 1, 3, 6, 9, 12, 18, and 24 months postoperatively. The trial aims to provide robust evidence for the efficacy and safety of this intervention in a vulnerable youth population.

The central hypothesis is that early re-initiation of semaglutide will significantly improve obesity, cardiometabolic risk, and eating behaviors in youth post-sleeve gastrectomy over 24 months.

Written by TitrateLab, separately from the study summarized above.